If you are in your 40s or 50s and feel like your body has started playing by a completely different set of rules, you are not imagining it. Women who have managed their weight successfully for years often find that the same habits, the same meals, the same exercise routines, stop producing the same results somewhere in the perimenopause transition. The scale moves up. The midsection changes. And no amount of willpower seems to make a dent.
This is not a discipline problem. It is a biology problem. And for a growing number of Long Island women, GLP-1 injections like Wegovy (semaglutide) and Zepbound (tirzepatide) are providing a clinical answer that works with what is happening in the body rather than against it.
What Perimenopause Actually Does to Your Metabolism
Most people know that estrogen declines during perimenopause and menopause. Fewer people understand what that decline actually does to the body’s metabolic systems, and why it makes weight gain so much harder to reverse through diet and exercise alone.
Estrogen plays a direct role in how the body stores fat. Before menopause, it helps direct fat storage toward the hips and thighs. As estrogen levels fall, that pattern shifts. Fat migrates toward the abdomen, and specifically toward visceral fat, the deep fat that wraps around the liver, pancreas, and intestines. Research published in the International Journal of Obesity tracked women longitudinally through the menopause transition and found that visceral fat increased significantly after menopause, even in women whose total body weight stayed relatively stable.
Visceral fat is metabolically active in ways that subcutaneous fat is not. It drives inflammation, promotes insulin resistance, and raises cardiovascular risk. It is also the hardest kind of fat to lose through caloric restriction alone.
The estrogen decline also disrupts sleep, which raises cortisol and throws hunger hormones out of balance. Ghrelin, the hormone that signals hunger, increases. Leptin, the hormone that signals fullness, becomes less effective. The result is that many perimenopausal women feel hungrier than they used to, feel less satisfied after eating, and carry more of the weight they gain in the worst possible place.
Why Dieting Alone Stops Working at This Stage of Life
The standard advice, eat less and move more, is not wrong. It is just insufficient when the underlying hormonal environment has changed this significantly.
A woman in perimenopause is not simply dealing with extra calories. She is dealing with accelerated fat redistribution, reduced insulin sensitivity, disrupted appetite signaling, and often a meaningful drop in resting metabolic rate. Research published in Scientific Reports found that perimenopausal and postmenopausal women showed significantly lower insulin sensitivity compared to premenopausal women, independent of body weight.
This matters because insulin resistance makes it harder for the body to use energy efficiently and easier for it to store fat. Cutting calories in that environment produces diminishing returns. The hunger is real. The fatigue is real. And the weight loss is slower, less consistent, and harder to maintain.
This is exactly the environment where GLP-1 medications work particularly well.
How Do GLP-1 Injections Help Women During Menopause?
GLP-1 receptor agonists work by mimicking a hormone your gut naturally produces after eating. They signal the brain to reduce hunger, slow the rate at which the stomach empties, and improve insulin signaling in the pancreas and liver. For women in perimenopause or menopause, this mechanism directly addresses several of the biological shifts that make weight loss so difficult at this stage.
The appetite suppression helps counteract the ghrelin and leptin dysregulation that estrogen decline causes. The improvement in insulin sensitivity targets the metabolic resistance that makes visceral fat so stubborn. And because these medications slow gastric emptying, they help reduce the blood sugar spikes that become more pronounced as estrogen falls.
The clinical data backs this up. A 2025 post-hoc analysis of the SURMOUNT clinical trials, conducted by researchers at NewYork-Presbyterian and Weill Cornell Medicine, examined results from 2,542 women across premenopausal, perimenopausal, and postmenopausal stages. Tirzepatide produced significant reductions in body weight, waist circumference, and waist-to-height ratio regardless of reproductive stage, and the researchers concluded that clinicians can prescribe the medication with confidence for women reporting menopause-related weight gain.
A separate 2024 study published in Menopause: The Journal of the North American Menopause Society looked at approximately 100 postmenopausal women on semaglutide and found meaningful weight loss alongside improvements in cardiovascular risk markers. Women who were also using hormone replacement therapy showed even stronger results.
What Kind of Results Can You Realistically Expect?
Results vary by individual, but the clinical benchmarks give a useful reference point. In the STEP 1 trial, participants using injectable semaglutide (Wegovy) lost an average of approximately 15 percent of body weight over 68 weeks. Tirzepatide (Zepbound) trials have shown average weight loss in the range of 20 to 22 percent in some populations.
For women in menopause specifically, the SURMOUNT analysis showed body weight reductions that were comparable to those seen in younger women, which addresses one of the most common concerns we hear: that these medications simply will not work as well once the hormonal picture has changed. The data says otherwise.
What matters as much as the total weight lost is where the weight comes from. GLP-1 medications are particularly effective at reducing visceral and abdominal fat, the exact fat that accumulates most aggressively during the menopause transition and that carries the greatest metabolic and cardiovascular risk.
One thing to plan for: because these medications can produce relatively rapid weight loss, muscle preservation requires attention. Declining estrogen already accelerates muscle loss in perimenopausal women. A treatment plan that includes adequate protein intake and resistance exercise is not optional at this stage of life. It is part of what makes the results sustainable and keeps the body strong through and after the process.
Is There Anything Special About How These Medications Are Used for Menopausal Women?
The medications themselves are the same. The dosing protocols are the same. What changes for women in perimenopause or menopause is the clinical picture a physician needs to account for when building the treatment plan.
Women at this stage of life often carry elevated cardiovascular risk, reduced bone density, and varying degrees of insulin resistance. They may also be managing other medications or considering hormone replacement therapy. The interaction between GLP-1 medications and HRT is actually a promising one: research suggests that estrogen may directly enhance GLP-1 receptor signaling, which could amplify the appetite-suppressing effect of the medication. Women on both therapies in the 2024 semaglutide study lost significantly more weight than those on semaglutide alone at every measured checkpoint.
This is not a one-size-fits-all situation, which is why physician-supervised care matters so much. A provider who understands how menopause affects metabolism, muscle mass, bone health, and cardiovascular risk can build a plan that produces better long-term results than a prescription alone ever will.
What Should Long Island Women Know Before Starting GLP-1 Treatment?
The most important thing to know is that these medications are a tool, not a complete solution on their own. The clinical trials that produced the strongest results combined GLP-1 therapy with structured lifestyle support, including nutrition guidance and physical activity. That combination consistently outperforms medication alone.
If you are in perimenopause or menopause and considering GLP-1 injections, a few practical points are worth understanding before your first appointment:
The dose escalation is gradual. Both Wegovy and Zepbound start at a low dose and increase over several months. This is intentional, and it significantly reduces the likelihood of nausea and other gastrointestinal side effects that some patients experience early in treatment.
Weight loss from these medications can include some lean muscle loss, particularly if protein intake is low and activity is limited. This is a more significant concern for menopausal women than for younger patients, and a good medical provider will monitor for it.
Results take time. Most patients begin to see meaningful changes within the first eight to twelve weeks, but the strongest results in clinical trials appeared at the one-year mark and beyond. Patience and consistency matter more than the number on the scale at week four.
FDA approval status: Wegovy (semaglutide 2.4 mg weekly injection) and Zepbound (tirzepatide 2.5 mg to 15 mg weekly injection) are both FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Neither is approved specifically for menopause-related weight gain, but the clinical evidence supporting their use in this population is strong and growing.
Taking the Next Step on Long Island
If you have spent the last few years feeling like your body is working against you, and you have done everything you are supposed to do, the problem is not effort. The hormonal changes of perimenopause and menopause are real, they are measurable, and they require a clinical response that matches their complexity.
GLP-1 injections like Wegovy and Zepbound offer that kind of response. They target the appetite dysregulation, the insulin resistance, and the visceral fat accumulation that make this stage of life so frustrating for so many women. The clinical data on their effectiveness in perimenopausal and postmenopausal patients is now substantial, and it consistently shows that these medications work.
Long Island Weight Loss Institute offers medically supervised GLP-1 treatment programs tailored to each patient’s individual history, including the hormonal and metabolic factors that are specific to women in midlife. Our team provides ongoing monitoring, nutritional guidance, and the kind of personalized attention that makes a real difference in long-term results. Consultations are available at our locations in East Meadow, Amityville, Smithtown, and Port Jefferson Station, as well as through telehealth.